Following Cipla's recent announcement to launch first stem cell derived skincare product Cutisera in India, Stempeutics Research Pvt Ltd, the developer of the product, now plans to tie up with dermatologists in Mumbai, Delhi, Bangalore, Chennai and Hyderabad to propagate its efficacy and affordability.

Priced at Rs. 2995 for 30ml - i.e 45$, similar type of product in the USA costs around 150$ for 15ml, i.e 300$ for 30ml. Globally few products are available. Two are from USA named Lumina and Reluma and one from Korea.

Says B N Manohar, MD, Stempeutics Research Pvt Ltd, "We are in the process of meeting dermatologists across the country and have concluded meetings in Mumbai and Delhi. In the next one week, we should be covering other metro cities and have received encouraging feedback from the doctors."

The active ingredients in the product have been tested for in-vitro efficacy using human foreskin fibroblast cultures. They have also been tested for safety and efficacy in preclinical models, upon the successful conclusion of which, a 3-month human volunteer study was also undertaken in India.

The Indian drug regulatory authority has approved the manufacturing and distribution of this product in India. The company also plans to target other markets and has registered in Malaysia. "We want to export products from Bangalore to south east market, Indonesia, including Sri Lanka. Each country has different requirements. We are planning to conduct studies and get approvals," he explains.

Cutisera has been developed by Bengaluru based Stempeutics using bio-active factors derived from human adult stem cells to enhance the rejuvenation of ageing skin. The product has been dermatologically tested with human volunteers in India with features of ageing skin over a period of 3 months and has also got DCGI approval for the same.

Manohar further informs, "In 2 to 3 months time, we produced 8,000 bottles and our goal is to sell out 50,000 in a year. We have competition from P&G, L’Oreal and Kaya’s product for a premium Indian market of 600 to 700 crores segment. "

Cutisera imparts significant improvement in fine lines and wrinkles, skin tone and its evenness, reduction in dark spots and pigmentation, and increase in skin firmness and skin hydration. The product has been developed using bio-active factors derived from human adult stem cells to enhance the rejuvenation of ageing skin. The active ingredients have been tested for in vitro and in vivo efficacy. This human study has demonstrated Cutisera's effectiveness as a powerful and yet soothing anti-ageing skin care product suitable for all skin types of Indian origin. The formulated product does not contain any stem cells.